Clinical Trial Update: A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma [Phase 2]

View source ↗

Summary

A Phase II study of tebentafusp in HLA-A*02:01 positive patients with advanced clear cell sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Sarcoma

Drugs mentioned

• Tebentafusp (tebentafusp)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS) | Phase 2 | Status: RECRUITING